Sökning: WFRF:(Pepin K) >
Effects of solriamf...
Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy
-
Malhotra, A. (författare)
-
Jr, P. J. S. (författare)
-
Pepin, J. L. (författare)
-
visa fler...
-
Schweitzer, P. (författare)
-
Lammers, G. J. (författare)
-
- Hedner, Jan A, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
Redline, S. (författare)
-
Chen, D. (författare)
-
Chandler, P. (författare)
-
Bujanover, S. (författare)
-
Strohl, K. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2022
- 2022
- Engelska.
-
Ingår i: Sleep Medicine. - : Elsevier BV. - 1389-9457. ; 100, s. 165-173
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (SunosiTM) 37.5 (OSA only), 75, 150, or 300 mg/d. Methods: In two 12-week, randomized, placebo-controlled trials and one 1-year open-label extension study, changes in weight were evaluated from baseline to end of study (week 12 or week 40 of the open -label extension [after up to 52 weeks of solriamfetol treatment]) in participants with OSA or narcolepsy. Results: After 12 weeks of solriamfetol treatment, median percent change in weight from baseline across all solriamfetol doses was-0.84%, compared with 0.54% for placebo, in participants with OSA; and-0.07%, compared with 3.08% for placebo, in participants with narcolepsy. After up to 52 weeks of solriamfetol treatment, overall median percent change in weight from baseline was-1.76%, which showed a dose-dependent pattern (75 mg, 0.57%; 150 mg,-1.2%; 300 mg,-2.5%).Results were similar in subgroups of participants with OSA or narcolepsy, with overall median percent changes in weight of-2.2% and-1.1%, respectively. After up to 52 weeks of solriamfetol treatment, the percentage of participants with weight loss >= 5% relative to baseline was 25.7% overall and increased in a dose -dependent manner (75 mg, 4.5%; 150 mg, 17.3%; 300 mg, 32.4%). Results were similar among sub-groups of participants with OSA or narcolepsy, with 26.4% and 24.2% of participants experiencing weight loss >= 5%, respectively. No weight-related treatment-emergent adverse events were serious.Conclusions: Solriamfetol treatment was associated with decreases in body weight in a dose-related manner.(c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Solriamfetol
- Sunosi
- JZP-110
- Lung
- Sleep apnea
- Obesity
- positive airway pressure
- oral jzp-110 adx-n05
- duration
- obesity
- metaanalysis
- wakefulness
- orexin
- adults
- cpap
- Neurosciences & Neurology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Malhotra, A.
-
Jr, P. J. S.
-
Pepin, J. L.
-
Schweitzer, P.
-
Lammers, G. J.
-
Hedner, Jan A, 1 ...
-
visa fler...
-
Redline, S.
-
Chen, D.
-
Chandler, P.
-
Bujanover, S.
-
Strohl, K.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Sleep Medicine
- Av lärosätet
-
Göteborgs universitet